Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Oct 18, 2018
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how treatment for esophageal cancer affects patients' quality of life. Specifically, it focuses on people who are receiving either neoadjuvant treatment (which is given before surgery) or definitive chemoradiation (which is a combination of chemotherapy and radiation given as the main treatment). The study will gather information using standardized questionnaires to understand how patients feel during and after their treatment, as well as any side effects and overall health outcomes.
To participate, individuals must be at least 18 years old and have been diagnosed with esophageal cancer, specifically certain types like squamous cell carcinoma or adenocarcinoma, without spreading to distant parts of the body (except for nearby lymph nodes). Participants will need to provide informed consent and be able to complete the questionnaires. The trial is currently recruiting and welcomes all genders. This study aims to provide valuable insights into the effects of treatment on daily life for patients with esophageal cancer, helping to improve care and support for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant metastases (except supraclavicular nodes)
- • indication for neoadjuvant or definitive chemoradiation using either cisplatin/5-FU or carboplatin/paclitaxel with curative intent
- • age \>= 18 years
- • written informed consent
- • ability to answer the standardized questionaires according to the treating physician
- Exclusion Criteria:
- • age \< 18 years
- • Treatment with palliative intent
- • distant metastases (except supraclavicular nodes)
- • second malignancy
- • Prior systemic treatment for esophageal Cancer
- • Treatment in an interventional study
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Trial Officials
Falk Roeder, MD
Principal Investigator
Ludwig-Maximilians Universität München
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials